Skip to content

A randomized, double-blind controlled study of Zhichan granules in the treatment of Parkinson's disease

A randomized, double-blind controlled study of Zhichan granules in the treatment of Parkinson's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003642
Enrollment
Unknown
Registered
2020-08-22
Start date
2021-04-22
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meeting the diagnostic criteria for Parkinson's disease; (2) Aged between 40 and 80 years; (3) Patients with grade 3 or below according to the improved Hoehn-Yahr grading method; (4) Meeting the criteria for diagnosis of TCM syndrome of liver-kidney Yin deficiency or deficiency of qi and blood. (5) TCM syndrome score >= 10. (6) Those who sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Those who had undergone "cell knife" surgery in the half year before the experiment; (2) Patients with severe hypertension (blood pressure >180/120), and poor blood pressure?control; (3) Mental illness, epilepsy, pregnant women and lactating women; (4) Patients with severe cerebral arteriosclerosis, cerebrovascular disease and?the resultant limb dysfunction; (5) Patients with severe heart failure, kidney failure, abnormal liver function, bone disease, etc. that affect the evaluation of the curative effect of this disease; (6) Alcoholism, drug addiction or severe mental impairment (including severe alzheimer's disease), thus unable to take drugs on time and cooperating with the examination; (7) Participants in other clinical trials in recent 2 months; (8) Patients with Parkinson's syndrome and Parkinson's superimposed syndrome; (9) Allergic constitution and allergic to known ingredients of test and control drugs.

Design outcomes

Primary

MeasureTime frame
NMS Quest;UPDRS;NMSS;

Secondary

MeasureTime frame
BDNF;IL;MDA;SOD;8-OHdG;TNF-alpha;Alpha-synuclein;

Countries

China

Contacts

Public ContactWentao Li

Shanghai Municipal Hospital of Traditional Chinese Medicine

lwt1132@163.com+86 13331882730

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026